Inventiva SACA

Inventiva to participate at the 7th Annual Truist Securities Life Sciences Summit

26 Apr 2021 16:00:00 By Nasdaq GlobeNewswire

Appointment of Martine Zimmermann as Independent Director to Inventiva’s Board of Directors

19 Apr 2021 16:00:00 By Nasdaq GlobeNewswire

Results of the votes of the Combined Shareholders’ Meeting of April 16, 2021

19 Apr 2021 12:00:00 By Nasdaq GlobeNewswire

Inventiva's Combined Shareholders Meeting of April 16, 2021 - Availability of the preparatory documents and methods for participating and voting

25 Mar 2021 13:00:00 By Nasdaq GlobeNewswire

Statement of total voting rights and shares forming the company’s share capital on March 10th, 2021

25 Mar 2021 10:43:35 By Nasdaq GlobeNewswire

Inventiva announces filing of its 2020 Universal Registration Document and 2020 Annual Report on Form 20-F

15 Mar 2021 17:00:00 By Nasdaq GlobeNewswire

2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States

04 Mar 2021 16:00:00 By Nasdaq GlobeNewswire

Inventiva announces collaboration on non-invasive biomarkers to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvemen

25 Feb 2021 16:00:00 By Nasdaq GlobeNewswire

Inventiva to participate at several investor conferences in March 2021

24 Feb 2021 16:00:00 By Nasdaq GlobeNewswire

Inventiva’s 2020 Full-Year Financial Results Presentation

23 Feb 2021 16:00:00 By Nasdaq GlobeNewswire

Full-Year 2020: Cash position and revenues

11 Feb 2021 16:00:00 By Nasdaq GlobeNewswire

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

15 Jan 2021 11:45:00 By Nasdaq GlobeNewswire

Inventiva annonce sa participation à la « 39th Annual J.P. Morgan Healthcare Conference »

06 Jan 2021 16:00:00 By Nasdaq GlobeNewswire

Inventiva announces design of Phase III clinical trial with lanifibranor in NASH

05 Jan 2021 16:00:00 By Nasdaq GlobeNewswire